🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation

Published 03/11/2019, 10:01 PM
Updated 07/09/2023, 06:31 AM
US500
-
MRK
-
PFE
-
BMY
-
EXEL
-

Pfizer, Inc. (NYSE:PFE) and partner Merck KGaA announced that the European Medicines Agency (EMA) has validated their type II variation application for PD-L1 inhibitor, Bavencio (avelumab) in combination with Inlyta for the treatment of patients with advanced renal cell carcinoma (RCC).

Per the regulatory agency, the application is complete and the EMA will now begin its review procedure.

The application was based on positive results from the phase III JAVELIN Renal 101 study, which showed that Bavencio and Inlyta significantly extended median progression-free survival (PFS) by more than five months compared with Sutent (sunitinib) as a first-line treatment for patients with advanced RCC.

We remind investors that the FDA has also accepted a supplemental Biologics License Application (sBLA) for Bavencio in combination with Inlyta for patients with advanced RCC for Priority Review, with a target action date in June 2019.

Inlyta is already approved in Europe for use in adult patients with advanced RCC after failure of prior treatment with Sutent or cytokine, while Bavencio is approved for the treatment of adults and pediatric patients aged 12 years or older with metastatic Merkel cell carcinoma (mMCC) and metastatic urothelial carcinoma (mUC).

Currently, avelumab is being developed for more than 15 types of tumors, including breast, gastric/gastro-esophageal junction, head and neck, Hodgkin’s lymphoma, melanoma, mesothelioma, Merkel cell carcinoma, non-small cell lung cancer, ovarian and urothelial carcinoma. These studies are part of the JAVELIN development program.

Pfizer’s stock has lost 0.8% in the past six months against the industry’s growth of 3%.

While the RCC market holds immense potential, competition is stiff. Last month, the FDA also granted priority review to Merck’s (NYSE:MRK) sBLA for Keytruda in combination with Inlyta for the first-line treatment of patients with advanced RCC based on the results of KEYNOTE-426, and has set a target action date of Jun 20, 2019.

Exelixis’ (NASDAQ:EXEL) Cabometyx is a dominant player in the market. The drug is approved for the treatment of patients with previously untreated advanced RCC and those with advanced RCC who have received prior anti-angiogenic therapy. The drug continues to gain market share with its broad label.

Competition has further stiffened up with the approval of Bristol-Myers’ (NYSE:BMY) Opdivo and Yervoy for the treatment of poor and intermediate risk first-line RCC.

Zacks Rank

Pfizer currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>




Pfizer Inc. (PFE): Free Stock Analysis Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.